Recruiting
Phase 1
Phase 2

BDTX-1535

Sponsor:

Black Diamond Therapeutics, Inc.

Code:

NCT05256290

Conditions

Non-Small Cell Lung Cancer

Advanced Non-Small Cell Squamous Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma

Metastatic Lung Cancer

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

silevertinib monotherapy

Study Details

Brief summary:

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.

Phase 1 enrollment is now complete. Phase 2 is currently ongoing.

Conditions

Non-Small Cell Lung Cancer

Advanced Non-Small Cell Squamous Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma

Metastatic Lung Cancer

NSCLC

Study ID

NCT05256290

Start date

Mar 31, 2022

Status verified date

Jul, 2026

Completion date

Jun, 2028

Anticipated

Primary completion date

Mar, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Phase 2 Eligibility:

Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:

  • Measurable disease by RECIST 1.1 criteria.
  • Adequate bone marrow or organ function.
  • Life expectancy of ≥ 3 months.
  • Sufficient performance status.
  • Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.
  • Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):

  • Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
  • Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
  • Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
  • Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):

  • Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
  • EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
  • For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.

Key Exclusion Criteria:

  • Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
  • Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
  • Any history of interstitial lung disease related to EGFR TKI use.
  • Symptomatic or radiographic leptomeningeal disease.
  • Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
  • Unresolved toxicity from prior therapy.
  • Significant cardiovascular disease.
  • Major surgery within 4 weeks of study entry or planned during study.
  • Ongoing or recent anticancer therapy or radiation therapy.
  • Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
  • Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
  • Poorly controlled gastrointestinal disorders.

Study Design

Enrollment

220 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)

  • Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M).
  • Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor
  • Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)

experimental: Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)

experimental: Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)

Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)

experimental: Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD.

experimental: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD.

Interventions

silevertinib monotherapy

Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Primary outcome measure

  • Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535) [ Time Frame: The first treatment 21-day cycle (Cycle 1) ]
  • Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535) [ Time Frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days) ]
  • Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose [ Time Frame: Through study completion, approximately 1 year ]

Central Contacts and Locations

Central contacts

BDTX Clinical Trial Navigation Service

(866) 955-4397blackdiamondtx@careboxhealth.com

Locations

University of Alabama

Recruiting

Birmingham, Alabama, United States, 35294

Contacts

Banner MD Anderson Cancer Center

Recruiting

Gilbert, Arizona, United States, 85234

Contacts

City of Hope Orange County Lennar Foundation Cancer Center

Recruiting

Irvine, California, United States, 92618

Contacts

Cedars Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Sibley Memorial Hospital Johns Hopkins Medicine

Recruiting

Washington D.C., District of Columbia, United States, 20016

Contacts

Mayo Clinic- Jacksonville

Recruiting

Jacksonville, Florida, United States, 32224

Contacts

Yanyan Lou

855-776-0015

Miami Cancer Institute - Baptist Health South Florida

Recruiting

Miami, Florida, United States, 33176

Contacts

UHP- University of Hawaii Cancer Center

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Evan Wu, MD

808-586-3010

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Mayo Clinic- Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Anastasios Dimou, MD

855-776-0015

Montefiore Medical Center

Recruiting

The Bronx, New York, United States, 10461

Contacts

University of Pittsburgh Medical Center - Hillman Cancer Center

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contacts

Jennifer Ruth

ruthj2@upmc.edu

Tennessee Oncology

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Inova Schar Cancer Institute

Recruiting

Fairfax, Virginia, United States, 22031

Contacts

Next Oncology

Recruiting

Fairfax, Virginia, United States, 22031

Contacts

Fred Hutchinson Cancer Center/University of Washington

Recruiting

Seattle, Washington, United States, 98109

Contacts

BC Cancer Vancouver

Recruiting

Vancouver, British Columbia, Canada, V5Z 4E6

Contacts

The Princess Margaret Cancer Centre

Recruiting

Toronto, Ontario, Canada, M5G 1X5

Contacts

More Information

Sponsor

Black Diamond Therapeutics, Inc.

Last update posted

Nov 18, 2026

Last verified

Jul, 2026

Keywords

  • EGFR alterations
  • EGFR L858R
  • EGFR Exon 19 del
  • EGFR inhibitor
  • intrinsic resistance NSCLC EGFR
  • acquired resistance NSCLC EGFR
  • intracranial disease
  • brain metastases
  • central nervous system metastases
  • CNS metastases
  • uncommon NSCLC EGFR mutations
  • C797S acquired resistance EGFR mutation
  • non-classical NSCLC EGFR mutations
  • classical NSCLC EGFR mutations
  • EGFR PACC NSCLC mutations
  • EGFR E709A/G/K/Q/V
  • EGFR E709_T710delinsD/T
  • EGFR G719A/C/D/R/S
  • EGFR G724S
  • EGFR L718Q/V
  • EGFR L747S/P, L747_A750delinsP, L747_P753delinsS
  • Second-site EGFR mutation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Black Diamond Therapeutics, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.